Arcellx Q4 2023 Earnings Report
Key Takeaways
Arcellx reported collaboration revenue of $63.1 million for the fourth quarter of 2023 and ended the quarter with $729.2 million in cash, cash equivalents, and marketable securities, extending the cash runway into 2027. Net income for the quarter was $20.5 million.
Expanded strategic partnership with Kite Pharma, Inc. to include co-development of anito-cel for lymphomas and Kite exercising its option to license ACLX-001.
Presented continued robust long-term responses from lead product candidate anito-cel evaluated in a Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma, at 65th ASH Annual Meeting and Exposition.
Ended the quarter with $729.2 million in cash, extending cash runway into 2027.
Collaboration revenue was $63.1 million for the quarter.
Arcellx
Arcellx
Forward Guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027.